On March 19, 2018 Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, reported that Ivan Bergstein, M.D., Stemline’s CEO, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 3:20 PM ET at the Westin New York Grand Central (Press release, Stemline Therapeutics, MAR 19, 2018, View Source [SID1234524891]). A live webcast of the presentation can be viewed on the company’s website at www.stemline.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 19, 2018 Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, reported that its management will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, taking place March 20-21 at the Westin New York Grand Central hotel in New York City (Press release, Molecular Templates, MAR 19, 2018, View Source [SID1234524890]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 19, 2018 Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, reported that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 17th Annual Healthcare Conference on, March 28, 2018 at 11:00 AM EDT at the Westin Grand Central Hotel in New York, NY (Press release, Histogenics, MAR 19, 2018, View Source;p=RssLanding&cat=news&id=2338678 [SID1234524888]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live audio webcast of the presentations on the "Investor Relations" page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.

On March 19, 2018 – Diplomat Pharmacy Inc. (NYSE: DPLO)reported that it will participate in Needham & Company’s 17th annual healthcare conference in New York City (Press release, Diplomat Speciality Pharmacy, MAR 19, 2018, View Source;Company-Healthcare-Conference/default.aspx [SID1234524887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.)

Interim CEO Jeff Park and Chief Financial Officer Atul Kavthekar are scheduled to present at 11:30 a.m. ET Wednesday, March 28.

Live audio-only webcasts of the presentation and related materials will be available on the investor relations section of Diplomat’s website at ir.diplomat.is. The webcast and presentation materials will be online for 90 days.

On March 19, 2018 Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, reported that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday March 21, 2018 at 3:55pm Eastern Time. Dr. Simpson will highlight the recent corporate developments and provide an overview of the Company (Press release, Delcath Systems, MAR 19, 2018, View Source;p=RssLanding&cat=news&id=2338779 [SID1234524886]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available at www.delcath.com/investors-events, and a replay will be available at the same address approximately one hour after the presentation for approximately 90 days.

The Oppenheimer 28th Annual Healthcare Conference is being held at the March 20-21, 2018 The Westin New York Grand Central Hotel from March 20-21, 2018.